Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed Median Overall Survival Exceeded 37 Months in First-Line Maintenance with IMDELLTRA and Either IMFINZI or TECENTRIQ® THOUSAND OAKS, Calif., Oct. 24, 2026 /PRNewswire/ -- Amgen (NASD

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery alone Results evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026 NEW BRUNSWICK, N.J., Oct. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today an

Presented first-in-class clinical proof-of-concept data in KRAS G12D mutant CRC with combination of QTX3034 and anti-EGFR ± chemotherapyCombinations demonstrated robust anti-tumor activity with no new safety signals in CRC patients, facilitating development for early lines of therapyAdvancing QTX6255, potential best-in-class pan-KRAS inhibitor, on track for IND filing in 4Q26Strong cash position with expanded Series D extension enabling runway through critical clinical data readouts RADNOR, Pa.

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to TRAEs Data informed FDA-aligned dose and regimen selection for upcoming PEDESTAL Phase 3 registrational trial, with initiation planned in the first half of 2027 and topline results anticipated in 2029Co

LAS VEGAS, Oct. 24, 2026 /PRNewswire/ -- With a healthcare system that embraces both modern medicine and Traditional Chinese medicine (TCM), Taiwan brings together herbal knowledge passed down over millennia, scientific evidence and modern pharmaceutical and biotechnology capabilities. Supported by the Department of Chinese Medicine and Pharmacy, Ministry of Health and Welfare, and organized by the Taiwan Institute of Economic Research, the Taiwan Traditional Chinese Medicine Pavilion will showc

BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit marked a milestone in Likang's international outreach, showcasing its scientific platform and clinical development programs. Convened by the Department of Health – Abu Dhabi under the theme "To Sense Is to Predict

In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses75% (18/24) disease control rate (DCR)17.8 months median Overall SurvivalExploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation of clinical data for BAT8008, a TROP2-targeted antibody-drug conjugate (ADC), in combination with BAT1308, an anti-PD-1 monoclonal antibody, at the 2026 European Society for Medical Oncology (ESMO) Congress. Professor Shaodong Hong of Sun Yat-sen University Cancer Center delivered a ra

Media ReleaseCOPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G

Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. The partners’ detailed data for a phase 3 win of their cancer vaccine intismeran autogene was set to be the highlight of the European Society for Medical Oncology (ESMO) Congress, given the honor of the coveted Presidential Symposium on Saturday. But an unexpected leak of the ESMO data on Thursday forced the partners to rework their plans and go public with their findings two